Prosecution Insights
Last updated: May 29, 2026

Leason Ellis LLP (Genentech)

6 pending office actions • 2 clients • 6 examiners • 6 art units • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
4
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

5
Overdue
0
Due this week
1
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (5)Due ≤ 30 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
3
Medium (50%)
0
Easy (0%)
3
Unknown (50%)

Rejection Statute Mix

BucketCases
§103 only3 (50%)
No statute on record3 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
WEN, SHARON X 1 56.5% +32.8%
GOMEZ RODRIGUEZ, JULIO WASHINGTON 1 45.8% +50.0%
OUSPENSKI, ILIA I 1 77.6% +20.3%
NOAKES, SUZANNE MARIE 1 73.1% +18.3%
WEHBE, ANNE MARIE SABRINA 1 57.6% +42.1%
ALLEN, MICHAEL D 1 32.6% +48.7%

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
16977547 CARTYRIN COMPOSITIONS AND METHODS FOR USE ALLEN, MICHAEL D 121d overdue
19285781 COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS WEN, SHARON X 56d overdue
17822240 COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME WEHBE, ANNE MARIE SABRINA 44d overdue
18051109 HYPERACTIVE PIGGYBAC TRANSPOSASES NOAKES, SUZANNE MARIE 30d overdue
18264782 GENETICALLY MODIFIED INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE THEREOF GOMEZ RODRIGUEZ, JULIO WASHINGTON 1d overdue
18334531 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS OUSPENSKI, ILIA I 28d

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Poseida Therapeutics, Inc. 4
GENENTECH, INC. 2

Top Art Units

Art UnitApps
16411
16371
16441
16561
16341
16711

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19285781 COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS Genentech, Inc. WEN, SHARON X 1641 Other Non-Final OA 56d overdue Pending Jul 30, 2025
18264782 GENETICALLY MODIFIED INDUCED PLURIPOTENT STEM CELLS AND METHODS OF USE THEREOF Poseida Therapeutics, Inc. GOMEZ RODRIGUEZ, JULIO WASHINGTON 1637 §103 Non-Final OA 1d overdue Pending Aug 09, 2023
18334531 METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS Genentech, Inc. OUSPENSKI, ILIA I 1644 Other Non-Final OA 28d Pending Jun 14, 2023
18051109 HYPERACTIVE PIGGYBAC TRANSPOSASES Poseida Therapeutics, Inc. NOAKES, SUZANNE MARIE 1656 Other Non-Final OA 30d overdue Pending Oct 31, 2022
17822240 COMPOSITIONS AND METHODS FOR DIRECTING PROTEINS TO SPECIFIC LOCI IN THE GENOME Poseida Therapeutics, Inc. WEHBE, ANNE MARIE SABRINA 1634 §103 Final Rejection 44d overdue Pending Aug 25, 2022
16977547 CARTYRIN COMPOSITIONS AND METHODS FOR USE Poseida Therapeutics, Inc. ALLEN, MICHAEL D 1671 §103 Final Rejection 121d overdue Pending Sep 02, 2020

Managing Leason Ellis LLP (Genentech)'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month